CA2434020A1 - Substituted diarylureas as stimulators for fas-mediated apoptosis - Google Patents
Substituted diarylureas as stimulators for fas-mediated apoptosis Download PDFInfo
- Publication number
- CA2434020A1 CA2434020A1 CA002434020A CA2434020A CA2434020A1 CA 2434020 A1 CA2434020 A1 CA 2434020A1 CA 002434020 A CA002434020 A CA 002434020A CA 2434020 A CA2434020 A CA 2434020A CA 2434020 A1 CA2434020 A1 CA 2434020A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- optionally substituted
- fas
- independently selected
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/42—Y being a hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27398801P | 2001-03-07 | 2001-03-07 | |
| US60/273,988 | 2001-03-07 | ||
| US10/082,802 | 2002-02-22 | ||
| US10/082,802 US6525091B2 (en) | 2001-03-07 | 2002-02-22 | Substituted diarylureas as stimulators for Fas-mediated apoptosis |
| PCT/US2002/006217 WO2002076930A2 (en) | 2001-03-07 | 2002-03-01 | Substituted diarylureas as stimulators for fas-mediated apoptosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2434020A1 true CA2434020A1 (en) | 2002-10-03 |
Family
ID=26767870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002434020A Abandoned CA2434020A1 (en) | 2001-03-07 | 2002-03-01 | Substituted diarylureas as stimulators for fas-mediated apoptosis |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1366021B1 (https=) |
| JP (1) | JP2004528311A (https=) |
| AT (1) | ATE366720T1 (https=) |
| AU (1) | AU2002306618B2 (https=) |
| CA (1) | CA2434020A1 (https=) |
| DE (1) | DE60221104T2 (https=) |
| ES (1) | ES2286267T3 (https=) |
| WO (1) | WO2002076930A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| US7645903B2 (en) | 2002-10-31 | 2010-01-12 | Ge Healthcare Bio-Sciences Ab | Use of urea variants as affinity ligands |
| WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| US12098117B2 (en) * | 2018-12-11 | 2024-09-24 | Duke University | Compositions and methods for the treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3214468A (en) * | 1959-08-14 | 1965-10-26 | Geigy Ag J R | Bis-(trifluoromethyl)-carbanilides |
| US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
| BR9814375A (pt) * | 1997-12-22 | 2002-05-21 | Bayer Ag | Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas |
| JP3887769B2 (ja) * | 1997-12-22 | 2007-02-28 | バイエル コーポレイション | 対称および非対称ジフェニル尿素を用いるp38キナーゼの阻害 |
| EP1071658B1 (en) * | 1998-04-17 | 2004-06-16 | Parker Hughes Institute | Btk inhibitors and methods for their identification and use |
-
2002
- 2002-03-01 AU AU2002306618A patent/AU2002306618B2/en not_active Ceased
- 2002-03-01 DE DE60221104T patent/DE60221104T2/de not_active Expired - Fee Related
- 2002-03-01 WO PCT/US2002/006217 patent/WO2002076930A2/en not_active Ceased
- 2002-03-01 ES ES02753691T patent/ES2286267T3/es not_active Expired - Lifetime
- 2002-03-01 CA CA002434020A patent/CA2434020A1/en not_active Abandoned
- 2002-03-01 AT AT02753691T patent/ATE366720T1/de not_active IP Right Cessation
- 2002-03-01 JP JP2002576193A patent/JP2004528311A/ja not_active Withdrawn
- 2002-03-01 EP EP02753691A patent/EP1366021B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE366720T1 (de) | 2007-08-15 |
| DE60221104T2 (de) | 2008-03-13 |
| EP1366021B1 (en) | 2007-07-11 |
| EP1366021A2 (en) | 2003-12-03 |
| AU2002306618B2 (en) | 2006-11-09 |
| WO2002076930A3 (en) | 2003-01-16 |
| DE60221104D1 (de) | 2007-08-23 |
| ES2286267T3 (es) | 2007-12-01 |
| WO2002076930A2 (en) | 2002-10-03 |
| JP2004528311A (ja) | 2004-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6525091B2 (en) | Substituted diarylureas as stimulators for Fas-mediated apoptosis | |
| JP6905053B2 (ja) | ベンジルフェニルエーテル誘導体、その調製方法、並びにその医薬組成物及び使用 | |
| JP4188416B2 (ja) | 有意なホルモン活性のないチロキシン類縁体による悪性腫瘍の治療方法 | |
| AU683654B2 (en) | Urea and amide derivatives and their use in the control of cell membrane potassium channels | |
| JP2575183B2 (ja) | 抗高脂血性および抗アテローム性動脈硬化性の尿素およびカルバメート化合物 | |
| AU2024200693A1 (en) | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof | |
| KR20160009667A (ko) | 염증의 예방 및 치료를 위한 크리오피린 억제제 | |
| JP2000513009A (ja) | カルシトニン擬似体 | |
| JP2016029044A (ja) | 変異cftrタンパク質の修飾因子としての化合物 | |
| JP2014527043A (ja) | Srcホモロジー2プロテインチロシンホスファターゼ−1を含むアゴニスト及びその治療方法 | |
| WO1994026260A1 (en) | METHODS AND COMPOUNDS FOR INHIBITING CELL PROLIFERATIVE DISORDERS CHARACTERIZED BY ABNORMAL abl ACTIVITY | |
| JP2020019807A (ja) | 化合物及びそれらの使用の方法 | |
| EP1366021B1 (en) | Substituted diarylureas as stimulators for fas-mediated apoptosis | |
| JP2003221376A (ja) | Cetp活性阻害剤 | |
| WO2000030683A1 (en) | Preventives and/or remedies for central nervous system diseases containing compounds having txa2 receptor antagonism and/or txa2 synthase inhibitory effect | |
| AU2002306618A1 (en) | Substituted diarylureas as stimulators for Fas-mediated apoptosis | |
| WO2012022780A1 (en) | 18-beta-glycyrrhetinic acid derivatives with anti-tumor activity | |
| JP5116207B2 (ja) | 神経保護、抗うつおよび抗虚血活性を有する新規アダマンタン誘導体、およびその製造法 | |
| CN114315754A (zh) | 一种异羟肟酸类化合物及其用途 | |
| JP3177245B2 (ja) | オキシスルホニル尿素acat阻害剤 | |
| KR890000175B1 (ko) | 치환된 페닐 알킬(피페라지닐) 프로필-(우레아 또는 티오우레아) 및 그의 제조방법 | |
| EP1368318B1 (en) | Calcilytic compounds | |
| US6255298B1 (en) | Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases | |
| AU2010301449B2 (en) | 2,3-dihydro-1H-indene-2-ylurea derivative and pharmaceutical application of same | |
| JPS6025969A (ja) | アレルギ−治療用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |